dr. kahl on considerations for treatment strategies in cll
Published 5 years ago • 254 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
1:35
dr. kahl on frontline therapy selection in cll
-
1:43
dr. kahl on ibrutinib in cll
-
1:53
dr. kahl on frontline btk inhibitor selection in cll
-
2:02
dr. kahl on promising research in chronic lymphocytic leukemia
-
2:05
dr. kahl on the impact of venetoclax in chronic lymphocytic leukemia
-
1:33
dr. kahl on the utility of tafasitamab/lenalidomide in dlbcl
-
0:54
dr. kahl on patient preference in treatment selection for cll
-
3:15
what is leukemia?
-
10:30
leukemia patient story: my 1st symptoms for cll | stephen's story (1/5) | the patient story
-
4:27
leigh's story: living well with chronic lymphocytic leukaemia (cll)
-
37:22
eha 2024 recap: optimizing the relapsed/refractory cll treatment pathway
-
12:46
fixed duration treatment strategies in cll
-
0:15
copy of dr. kahl on patient preference in treatment selection for cll
-
1:51
dr. smith on frontline treatment considerations in cll
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:29
dr. james on update of ibrutinib for chronic lymphocytic leukemia
-
1:20
dr. byrd provides an update on ibrutinib in cll
-
1:04
dr. kay discusses combination strategies in cll
-
1:17
dr. kahl on treatment strategies for indolent lymphoma
-
1:41
dr. kipps on ibrutinib versus chlorambucil in treatment-naïve cll/sll
-
1:09
dr. chanan-khan on ibrutinib as backbone of treatment for cll
-
1:28
dr. ma on the utility of btk inhibitors in relapsed/refractory cll